Robert W. Baird reiterated their outperform rating on shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) in a report published on Friday. They currently have a $102.00 price target on the stock.

Several other equities research analysts have also issued reports on SRPT. Vetr raised Sarepta Therapeutics from a strong sell rating to a buy rating and set a $17.28 price objective for the company in a research note on Thursday, June 2nd. Jefferies Group reiterated a sell rating and issued a $7.00 price target on shares of Sarepta Therapeutics in a report on Thursday, June 2nd. Oppenheimer Holdings Inc. reiterated an outperform rating and issued a $60.00 price target on shares of Sarepta Therapeutics in a report on Friday, June 3rd. JMP Securities reiterated a sell rating and issued a $10.00 price target on shares of Sarepta Therapeutics in a report on Friday, June 3rd. Finally, Leerink Swann reiterated an underperform rating and issued a $5.00 price target on shares of Sarepta Therapeutics in a report on Friday, June 3rd. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. Sarepta Therapeutics has an average rating of Buy and a consensus price target of $54.44.

Shares of Sarepta Therapeutics (NASDAQ:SRPT) opened at 61.10 on Friday. The company’s market capitalization is $2.93 billion. Sarepta Therapeutics has a 52-week low of $8.00 and a 52-week high of $63.73. The company’s 50 day moving average price is $35.91 and its 200 day moving average price is $23.83.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) EPS for the quarter, missing analysts’ consensus estimates of ($1.19) by $0.16. During the same quarter in the prior year, the company earned ($0.87) earnings per share. On average, analysts predict that Sarepta Therapeutics will post ($4.16) EPS for the current year.

In related news, SVP David T. Howton sold 7,000 shares of the company’s stock in a transaction that occurred on Thursday, September 22nd. The stock was sold at an average price of $60.00, for a total value of $420,000.00. Following the transaction, the senior vice president now directly owns 28,453 shares in the company, valued at $1,707,180. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Edward M. Md Kaye sold 24,557 shares of the company’s stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total value of $736,710.00. Following the completion of the transaction, the chief executive officer now owns 76,983 shares in the company, valued at $2,309,490. The disclosure for this sale can be found here. Insiders own 10.90% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Harbour Capital Advisors LLC acquired a new position in Sarepta Therapeutics during the second quarter worth approximately $335,000. Schwab Charles Investment Management Inc. boosted its position in Sarepta Therapeutics by 1.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 153,816 shares of the company’s stock worth $2,934,000 after buying an additional 2,766 shares in the last quarter. Stifel Financial Corp boosted its position in Sarepta Therapeutics by 5.4% in the second quarter. Stifel Financial Corp now owns 23,076 shares of the company’s stock worth $441,000 after buying an additional 1,178 shares in the last quarter. American Century Companies Inc. acquired a new position in Sarepta Therapeutics during the second quarter worth approximately $651,000. Finally, First Allied Advisory Services Inc. boosted its position in Sarepta Therapeutics by 6.7% in the second quarter. First Allied Advisory Services Inc. now owns 12,800 shares of the company’s stock worth $245,000 after buying an additional 800 shares in the last quarter. Hedge funds and other institutional investors own 65.29% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.